Piramal Pharma Q2 Results: Piramal Pharma post net loss of Rs 37 crore in Q2FY23
The complex hospital generic business that contributes one-third of revenues grew 12% YoY to Rs 562 crore. Piramal said it is witnessing strong inhalation anesthesia (IA) sales in the US market with continued volume growth driving market share gains. The company added IA capacities in India to serve the growing demand from non-US markets.
